Poziotinib is an investigational, orally administered, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations.
> To read the latest news about poziotinib, or to watch a video on its mechanism, click here.
Poziotinib is designed to be small and flexible.
Poziotinib is an investigational drug not approved by the FDA.
In pre-clinical models of cancer, poziotinib was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death.
Non Small Cell Lung Cancer
SPI-POZ-202 (Phase 2): EGFR and HER2 Exon 20 Insertion Mutations Locally Advanced or Metastatic NSCLC
SPI-POZ-201 (Phase 2): HER2+ Metastatic Breast Cancer
Spectrum Pharmaceuticals to Present Data from Phase 2 Clinical Trial for Poziotinib at Upcoming Medical ConferenceRead More
Spectrum Announces Poziotinib Data Being Presented at the IASLC 2019 World Conference on Lung CancerRead More
Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer PatientsRead More
Spectrum Pharmaceuticals Announces Release of Poziotinib Abstract as Part of the IASLC 19th World Conference on Lung CancerRead More
Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer CenterRead More
Spectrum Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo Fisher ScientificRead More
Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in ChicagoRead More
Update of MD Anderson’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer PatientsRead More
Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER2Read More
Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18, 2017Read More
Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion MutationsRead More
Spectrum Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung CancerRead More